MicuRx Pharmaceuticals
Foster City · Founded 2007
About MicuRx Pharmaceuticals
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.
Company Facts
- Founded: 2007
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $268.2M
- Funding stage: IPO
- Last round: Series E (Dec 2020)
- Ticker: sse:688373
- Website: http://micurx.com
- Phone: 510-782-2021
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/micurx-pharmaceuticals-62149 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.